Month: May 2021

May 6, 2021
Vutrisiran receives Fast Track Designation from FDA
Alnylam has submitted a new drug application (NDA) to the FDA for vutrisiran, which could bring another treatment option to patients with ATTR amyloidosis. Vutrisiran received “Fast Track” Designation, which is a process designed to expedite the review of drugs...
Read More
- Categories
- Archives
- May 2023 (1)
- March 2023 (2)
- February 2023 (1)
- October 2022 (3)
- July 2022 (1)
- June 2022 (1)
- April 2022 (1)
- February 2022 (2)
- November 2021 (2)
- September 2021 (1)
- June 2021 (1)
- May 2021 (1)
- March 2021 (1)
- February 2021 (1)
- January 2021 (2)
- December 2020 (1)
- November 2020 (2)
- October 2020 (1)
- September 2020 (1)
- July 2020 (1)
- February 2020 (2)
- January 2020 (2)
- December 2019 (1)
- November 2019 (3)
- October 2019 (1)
- September 2019 (3)
- August 2019 (1)
- June 2019 (1)
- May 2019 (2)
- March 2019 (2)
- February 2019 (1)
- January 2019 (1)
- December 2018 (3)
- October 2018 (2)
- September 2018 (1)
- August 2018 (2)
- July 2018 (2)
- April 2018 (3)
- March 2018 (2)
- February 2018 (3)
- January 2018 (2)
- December 2017 (4)
- November 2017 (2)
- October 2017 (1)
- August 2017 (1)
- July 2017 (1)
- June 2017 (1)
- April 2017 (1)
- February 2017 (1)
- December 2016 (2)
- October 2016 (2)
- September 2016 (1)
- July 2016 (3)
- June 2016 (4)
- May 2016 (1)
- April 2016 (2)
- March 2016 (1)
- February 2016 (2)
- December 2015 (1)
- November 2015 (2)
- October 2015 (1)
- September 2015 (1) More